Please ensure Javascript is enabled for purposes of website accessibility

What Happened in the Stock Market Today

By Jim Crumly – Updated Jul 19, 2017 at 3:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On a record day for indexes, shares of Vertex Pharmaceuticals soared on drug trial results and CSX slumped despite a surprisingly good quarter.

Stocks advanced steadily through the day, with the Dow Jones Industrial Average (^DJI -1.62%) and S&P 500 (^GSPC -1.72%) both closing at record highs.

Today's stock market

Index Percentage Change Point Change
Dow 0.31% 66.02
S&P 500 0.54% 13.22

Data source: Yahoo! Finance.

Energy stocks led the market, as crude oil climbed to over $47 a barrel; the SPDR S&P Oil & Gas Exploration & Production ETF (XOP -8.06%) gained 3.7%. Biotechs also advanced, with the iShares Nasdaq Biotechnology ETF (IBB -1.21%) adding 1.4%.

As for individual stocks, shares of Vertex Pharmaceuticals (VRTX -1.01%) soared after releasing results from clinical studies, and CSX Corporation (CSX -3.12%) fell despite delivering a solid quarter.

Graph of rising stock prices

Image source: Getty Images.

Vertex soars on cystic fibrosis trials

Positive results from new combination drugs for cystic fibrosis sent Vertex Pharmaceuticals stock 21% higher today. The data was from phase 1 and phase 2 studies of three different triple combination regimens for patients that have a severe and difficult-to-treat form of the disease. The patients showed a significant improvement in an important measure of breathing function, and positive safety data showed that the drugs were well-tolerated.

"These safety and efficacy data are clear and compelling, indicating significant potential benefit for people with CF from each of these three different triple combination regimens," said Jeffrey Chodakewitz, M.D., executive VP and chief medical officer. "We will be collecting and evaluating additional data from these and other studies and will make a decision on which regimen(s) to take forward into pivotal program(s), which we expect to begin in the first half of 2018."

Vertex already has a strong leadership position in drugs for cystic fibrosis. The reason for the excitement over these results is the potential for expanding the number of patients that can be successfully treated. Patients in the study had particular mutations that caused their disease to be unresponsive to existing therapies, and the study data released yesterday were the first to demonstrate the potential to treat the underlying cause of the disease in these patients.

CSX stays on track

Railroad company CSX reported a strong quarter last night that beat expectations, but the stock fell 5% on concerns about the rest of the year. Revenue came in at $2.93 billion, up 8% from the year before. GAAP earnings per share were up 17% to $0.55 ($0.64 after adjusting for restructuring charges), compared to analyst expectations of $0.59. The company reaffirmed previous guidance for full-year EPS growth of 25% to around $2.26, but analysts had been thinking it would be able to earn $2.30. 

Coal shipments, particularly for export, were strong, with a 27% increase in revenue. Revenue from intermodal shipments was also a bright spot, up 7%. The company was able to make gains from increased pricing, with "same store" sales pricing up 3.7% over a year ago. CSX's efficiency improvements are paying off as well, with $90 million in efficiency gains during the quarter, exceeding inflation in costs.

"We are implementing Precision Scheduled Railroading on an expedited timetable, converting switching operations, balancing the network, streamlining resources and getting more out of our assets," said CEO E. Hunter Harrison in the press release. "Although there still remains a lot to be done, we are confident that these initiatives will drive improved customer service, greater resource efficiency and superior shareholder value."

The results were generally good across the board, but investors appeared to be concerned about what's ahead for the second half, despite the fact that management held firm on guidance. With CSX stock up a strong 44% in the year so far, it may be that investors' hopes were getting a little ahead of reality.

Jim Crumly owns shares of Vertex Pharmaceuticals. The Motley Fool recommends CSX and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CSX Corporation Stock Quote
CSX Corporation
CSX
$27.68 (-3.12%) $0.89
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$283.45 (-1.01%) $-2.89
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$29,590.41 (-1.62%) $-486.27
S&P 500 Index - Price Return (USD) Stock Quote
S&P 500 Index - Price Return (USD)
^GSPC
$3,693.23 (-1.72%) $-64.76
SPDR Series Trust - SPDR S&P Oil & Gas Exploration & Production ETF Stock Quote
SPDR Series Trust - SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$118.61 (-8.06%) $-10.40
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$115.32 (-1.21%) $-1.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.